Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
This study is looking at a new way to image multiple sclerosis (MS) using a special MRI scan. It involves an injection of HP 13C pyruvate during an MRI to see how MS lesions, white matter, and the whole brain use energy. The goal is to see if this imaging method can predict how well people with relapsing-remitting MS (RRMS) will respond to anti-CD20 therapy. You might be able to join if you are 18 or older, have RRMS, haven't taken disease-modifying therapies (DMTs) for at least two years, and plan to start anti-CD20 therapy. The study aims to enroll 40 participants.
- Study design
- This is an interventional study planning to enroll 40 participants with relapsing-remitting MS. It is a single-arm study, meaning all participants will receive the same intervention.
- What's involved
- You would receive HP 13C pyruvate injections during MRI scans. Some participants will have a second injection for a repeatability study. You will also have blood draws and standard MS clinical assessments over approximately one year.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measures changes up to 1.5 months after starting treatment, with overall study follow-up from initiation to up to 15 months after the last subject is enrolled.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
At a glance
Conditions
NCT07510607
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Byers Hall
San Francisco, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Ari Green, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To determine the percent changes in MS lesions, white matter, and whole brain HP 13C pyruvate metabolism measures between the pre-treatment scan and the scan obtained 1.5-months following treatment initiation.From study initiation to up to 15 months after enrollment of last subject.
Percent changes in lesion HP 13C pyruvate metabolism measures. The following metabolism measures will be assessed at baseline and at 1.5-months following treatment initiation * Peak HP 13C lactate/pyruvate and bicarbonate/pyruvate signal-to-noise ratio * HP 13C lactate/pyruvate and bicarbonate/pyruvate AUC ratio * Metabolic rate constants kPL and kPB in inverse seconds.